3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Uterine Cervical Neoplasms
6
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Lung Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Cholangiocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Melanoma
1
Locally Advanced Pancreatic Cancer
1
Locally Advanced Cervical Cancer
1
Liver Neoplasms
1
Liposarcoma
1
Kidney Neoplasms
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Docetaxel
5
S 1 (combination)
2
Carboplatin
2
zimberelimab
1
surufatinib
1
quemliclustat
1
pemigatinib
1
nimotuzumab
1
lorlatinib
1
cemiplimab
1
Vinorelbine
1
Pemetrexed
1
Paclitaxel
1
Gene Expression Profiling
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Non-Small Cell Lung Cancer
×
zimberelimab
×
Clear all
NCT05676931
2026-06-01
EDGE-Lung
Gilead Sciences
Phase 2
Active not recruiting
400 enrolled